Your browser is no longer supported. Please, upgrade your browser.
Agenus Inc.
Index- P/E- EPS (ttm)-1.06 Insider Own0.40% Shs Outstand192.97M Perf Week-1.31%
Market Cap565.91M Forward P/E- EPS next Y-1.08 Insider Trans0.00% Shs Float173.55M Perf Month8.08%
Income-181.10M PEG- EPS next Q-0.24 Inst Own52.30% Short Float15.80% Perf Quarter-42.67%
Sales88.20M P/S6.42 EPS this Y-31.40% Inst Trans-0.18% Short Ratio8.09 Perf Half Y-25.31%
Book/sh-1.06 P/B- EPS next Y-2.50% ROA-88.50% Target Price- Perf Year18.97%
Cash/sh0.53 P/C5.66 EPS next 5Y- ROE85.00% 52W Range2.28 - 5.95 Perf YTD-5.35%
Dividend- P/FCF- EPS past 5Y1.40% ROI- 52W High-49.41% Beta1.38
Dividend %- Quick Ratio- Sales past 5Y28.90% Gross Margin97.30% 52W Low32.02% ATR0.17
Employees359 Current Ratio0.90 Sales Q/Q-9.30% Oper. Margin- RSI (14)51.20 Volatility6.33% 6.24%
OptionableYes Debt/Eq- EPS Q/Q10.60% Profit Margin- Rel Volume0.60 Prev Close3.07
ShortableYes LT Debt/Eq- EarningsMay 06 BMO Payout- Avg Volume3.39M Price3.01
Recom1.30 SMA203.95% SMA50-0.62% SMA200-18.52% Volume2,086,897 Change-1.95%
Nov-19-19Resumed B. Riley FBR Buy $6
Apr-22-19Initiated B. Riley FBR Buy
Oct-28-16Downgrade H.C. Wainwright Buy → Neutral $10 → $5
Oct-27-16Reiterated Maxim Group Buy
Mar-11-16Upgrade Maxim Group Hold → Buy $7
Dec-16-15Initiated Jefferies Buy
Oct-27-15Downgrade Maxim Group Buy → Hold
Jul-27-15Reiterated MLV & Co Buy $9 → $11
Jun-11-15Initiated Oppenheimer Outperform $14
Jan-12-15Reiterated Maxim Group Buy $10 → $11
Jan-09-15Reiterated MLV & Co Buy $6 → $9
Jan-09-15Reiterated Maxim Group Buy $10 → $11
Dec-19-14Reiterated Maxim Group Buy $8 → $10
May-08-14Reiterated Maxim Group Buy $17 → $11
Mar-14-14Reiterated MLV & Co Buy $9 → $11
Oct-08-13Reiterated Maxim Group Buy $19
Jan-05-12Initiated William Blair Outperform
Dec-01-11Initiated Global Hunter Securities Buy $6
May-06-21 03:55PM  
Apr-28-21 05:30PM  
Apr-22-21 04:05PM  
Apr-19-21 08:30AM  
Apr-14-21 08:30AM  
Apr-10-21 08:35AM  
Apr-06-21 08:30AM  
Mar-15-21 04:00PM  
Mar-10-21 04:33PM  
Mar-08-21 12:30PM  
Mar-02-21 08:30AM  
Feb-09-21 05:06PM  
Feb-05-21 07:43AM  
Feb-04-21 08:30AM  
Jan-31-21 01:00AM  
Jan-26-21 08:30AM  
Jan-19-21 12:09PM  
Dec-13-20 09:44PM  
Dec-03-20 07:45AM  
Dec-01-20 08:00AM  
Nov-25-20 01:28PM  
Nov-16-20 07:04PM  
Nov-13-20 02:43PM  
Nov-12-20 09:00AM  
Nov-11-20 07:30AM  
Nov-10-20 08:45AM  
Nov-09-20 08:15AM  
Nov-05-20 08:00AM  
Nov-02-20 02:39PM  
Oct-30-20 03:30AM  
Oct-29-20 09:05AM  
Oct-22-20 12:33PM  
Oct-20-20 10:34AM  
Oct-14-20 05:00PM  
Oct-13-20 08:30AM  
Oct-01-20 07:13AM  
Sep-21-20 12:58PM  
Sep-18-20 10:13AM  
Sep-17-20 05:06PM  
Sep-11-20 10:28AM  
Sep-10-20 02:27PM  
Aug-31-20 08:00AM  
Aug-27-20 03:30PM  
Aug-26-20 02:46PM  
Aug-19-20 08:30AM  
Aug-06-20 11:55AM  
Aug-05-20 12:00PM  
Jul-21-20 01:31PM  
Jul-13-20 12:00PM  
Jul-05-20 03:40PM  
Jul-03-20 10:25AM  
Jun-26-20 12:00PM  
Jun-25-20 11:30AM  
Jun-24-20 04:53PM  
Jun-23-20 10:34AM  
Jun-22-20 09:43AM  
Jun-17-20 11:06AM  
Jun-16-20 08:12AM  
Jun-08-20 02:32PM  
Jun-06-20 11:31AM  
Jun-05-20 12:37AM  
Jun-03-20 07:39AM  
Jun-02-20 11:30AM  
Jun-01-20 09:21AM  
May-29-20 01:28PM  
May-28-20 09:42AM  
May-26-20 05:47PM  
May-14-20 11:56AM  
May-13-20 09:54AM  
May-11-20 12:00PM  
May-08-20 07:30PM  
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGF TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
INCYTE CORP10% OwnerJun 17Sale3.66141,920518,83116,972,968Jun 18 05:30 PM
INCYTE CORP10% OwnerJun 16Sale3.6672,080264,00717,114,888Jun 18 05:30 PM
INCYTE CORP10% OwnerJun 15Sale3.57384,0251,372,16017,186,968Jun 15 08:47 PM
INCYTE CORP10% OwnerJun 12Sale3.589,10032,55617,570,993Jun 15 08:47 PM
INCYTE CORP10% OwnerJun 11Sale3.77183,875692,78617,580,093Jun 15 08:47 PM